Short answer
Aura Biosciences, Inc. (AURA) filed an 8-K current report with the SEC on July 8, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1). Board expanded from six to seven directors with Jeremy Bender appointed as an independent Class II director through 2029.
Aura Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expanded from six to seven directors with Jeremy Bender appointed as an independent Class II director through 2029
- Bender joins Compensation and Nominating and Corporate Governance committees
- Initial equity grant: options for 60,000 shares plus RSUs covering 30,000 shares, vesting over three years
- Updated director retainers: $40,000 board service, plus committee fees up to $20,000 for Audit chair
- Director award sizes increased to 60,000 options and 30,000 RSUs initially, capped at $800,000 aggregate value
Item EX-99.1 · Exhibit EX-99.1
- Jeremy Bender appointed independent director, adding late-stage development, commercialization and oncology transaction expertise
- Appointment strengthens governance as Aura advances bel-sar toward potential regulatory approval
- Phase 3 CoMpass enrollment complete, making topline data and regulatory execution key near-term catalysts
- Bender previously led Day One through OJEMDA approval and its approximately $2.5 billion Servier acquisition
- Regulatory approval, clinical data and cash sufficiency remain material execution risks for investors
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aura Biosciences, Inc. 8-K filings
Get the next AURA 8-K as it lands
Follow AURA for push alerts, or ask the research agent what this filing means.